Pharmaceutical company shifts focusAMAG Pharmaceuticals recently announced several changes to its supply chain management strategy that the company is hoping will reduce its operating expenses.

The company is now focusing on advancing its product Feraheme, which is used for the treatment of anemia in adult chronic kidney disease patients. AMAG is shifting to an outsourced manufacturing model in an effort to reduce internal development expenses, which will entail closing a manufacturing facility in Massachusetts.

“The decision to eliminate positions is never easy and I want to thank the impacted individuals who have contributed greatly to AMAG over the years,” said William Heiden, president and chief executive officer of AMAG. "Today’s announcement signals a continuation of AMAG’s transformation into a highly focused, commercially oriented specialty pharmaceutical company."

Heiden also said the company will look to launch its products in international markets even as it curtails certain activities in the manufacturing and development spheres.

According to an Accenture report, more pharmaceutical companies have trimmed operational expenses to cut costs during the economic downturn, due in part to rising R&D costs that have prevented lucrative innovations.
Share To:

Strategic Sourceror

Post A Comment:

0 comments so far,add yours